New antibody treatment shows potential against dengue virus

Dengue fever, a mosquito-borne disease affecting millions in tropical regions, has long been a medical challenge.

Historically, patients diagnosed with the virus received only supportive care, as there have been no FDA-approved antiviral treatments.

However, science is now shifting from generalized supportive care toward a precise, targeted approach using engineered antibodies.

A major hurdle in dengue treatment has been the risk of 'enhancement,' where the immune system reacts poorly to a secondary infection.

Researchers are testing monoclonal antibodies like AV-1, which aim to reduce symptoms and speed up recovery.

Simultaneously, scientists are developing bispecific antibodies that not only target the virus but also block the 'cytokine storm'—the dangerous, overactive inflammatory response that causes organ damage.

Furthermore, broadly neutralizing antibodies (bNabs) are being identified that can tackle all four strains of the dengue virus at once.

By modifying these antibodies for longer-lasting effects and improved safety, scientists are paving the way for a future where dengue can be treated with precision, potentially offering hope against other related viruses like Zika.